Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PHAT

PHAT - Phathom Pharmaceuticals Inc Stock Price, Fair Value and News

$13.84-0.39 (-2.74%)
Market Closed

57/100

PHAT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

57/100

PHAT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$15.24

Target 3M

$13.92

Target 6M

$14.35

PHAT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PHAT Price Action

Last 7 days

1.7%

Last 30 days

-19.6%

Last 90 days

4.0%

Trailing 12 Months

121.4%

PHAT RSI Chart

PHAT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PHAT Valuation

Market Cap

984.6M

Price/Earnings (Trailing)

-3.59

Price/Sales (Trailing)

6.69

Price/Free Cashflow

-4.37

PHAT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$15.24

Target 3M

$13.92

Target 6M

$14.35

PHAT Fundamentals

PHAT Revenue

Revenue (TTM)

147.2M

Rev. Growth (Yr)

202.74%

Rev. Growth (Qtr)

25.32%

PHAT Earnings

Earnings (TTM)

-274.6M

Earnings Growth (Yr)

64.98%

Earnings Growth (Qtr)

60.46%

PHAT Profitability

Operating Margin

87.25%

Return on Equity

64.98%

Return on Assets

-114.26%

Free Cashflow Yield

-22.89%

PHAT Investor Care

Shares Dilution (1Y)

4.04%

Diluted EPS (TTM)

-3.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202581.9M114.0M147.2M0
202414.3M28.0M41.6M55.3M
2023000682.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Phathom Pharmaceuticals Inc

PHAT
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
 CEO
 WEBSITEphathompharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES112

Phathom Pharmaceuticals Inc Frequently Asked Questions

PHAT is the stock ticker symbol of Phathom Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Phathom Pharmaceuticals Inc is 984.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PHAT's fair value in chart for subscribers.

The fair value guage provides a quick view whether PHAT is over valued or under valued. Whether Phathom Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Phathom Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PHAT.

As of Wed Jan 28 2026, PHAT's PE ratio (Price to Earnings) is -3.59 and Price to Sales (PS) ratio is 6.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PHAT PE ratio will change depending on the future growth rate expectations of investors.